Navigation Links
SPO Medical to Conduct Live Investor Meeting on April 29, 2008
Date:4/10/2008

Using WallStreet VIPs' New Platform to Reach Wide Investor Audience

SPO Medical Inc. (SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, announced today that it will be delivering a live, virtual investor presentation, using WallStreet VIPs' new platform on April 29, 2008 at 1 PM Eastern Daylight Time (EDT).

NEW YORK, April 10 /PRNewswire-FirstCall/ -- "SPO Medical is a company on the move, though many investors still are not familiar with us," said Michael Braunold, President and Chief Executive Officer of SPO Medical. "We just reported our 2007 full year results with record sales; we added two new professional products, the finger PulseOx 6000(TM) and the hand-held PulseOx 6100(TM), and increased our network of distributors to 38 countries. Using WallStreet VIPs, we disseminate our story to the investor community broadcasting directly on the internet. It's a very effective way to reach out to the broader investor community, since presenters and investors can meet easily and conveniently from their respective offices."

"WallStreet VIPs is a 21st century productivity solution to the challenges of scheduling quality time for live meetings and provide great value added for every public company's comprehensive Investor Relations strategy in today's global village and permanent time constraints," stated Jerry Cahn, Ph.D., J.D., President of WallStreet VIPs. "Investor meetings are the life-blood of public companies. They enable the companies to maintain contact with the investor community educating and updating them on the company's business strategy and developments. CEOs traditionally engage in road shows traveling from city-to-city to meet investors impacting their time and attention that should be devoted to running their businesses."

For a free invitation to SPO Medical's virtual meeting, please register at http://www.WallStreetVIPs.com

About SPO Medical

SPO Medical (SPOM) a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-saving and life-enhancing information within four key markets: medical care; home and remote-care; sports and wellness; and safety and security. Its patented technology uses information gathered from the reflectance of light on the human blood stream, in a non-invasive manner, to monitor key vital signs. The Company distributes its products through a network of distributors and also licenses its technologies to appropriate client corporations for commercialization and distribution. For more information, visit http://www.spomedical.com.

About Wall Street VIPs

WallStreet VIPs is the 21st century productivity solution to the challenges of scheduling quality time, live meetings with potential and existing investors. When integrated with face-to-face meetings for the most serious investors making commitments, VIPs become a key part of every company's comprehensive investor relations strategy. WallStreet VIPs coordinates the whole program, scheduling the event, inviting qualified investors, coaching the presenter on using the platform, helping make the investor presentation compelling and providing details on the attending audience. For details, see: http://www.WallStreetVIPs.com.

Safe Harbor:

This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, changes in economic conditions generally and the medical devices market specifically, changes in technology, legislative or regulatory changes that affect us, the availability of working capital, the introduction of competing products, market acceptance of our new products, changes in our operating strategy or development plans and the risks and uncertainties discussed under the heading "Risk Factors" in Item 1 of our Annual Report on Form 10-KSB for the fiscal year ended December 31, 2007. We undertake no obligation to revise or update any forward-looking statement for any reason.

Investor Contacts

SPO Medical: Target 3 Communications:

Michael Braunold, President & CEO Eugene Feyman, Director

info@spomedical.com eugene@target3.com

+1-805-823-8163 +1-646-827-0009


'/>"/>
SOURCE SPO Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ANN ARBOR, Mich. , Dec. 7, 2016 ... breakthrough immune modulatory medicines, announced today the initiation of ... therapeutic candidate, LYC-30937- E nteric C oated, in ... disease that is estimated to affect as many as ... , with approximately 1.5 - 3 million cases being ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... for SmartBiome -- a novel metagenomic deep-sequencing research platform. SmartBiome combines the ... of hundreds of different genes. The selective early access program is open ...
(Date:12/6/2016)... ... December 06, 2016 , ... The ... asking the Federal Drug Administration (FDA) to consider OA as a serious disease. ... concerned about the growing population of OA patients, many of whom may experience ...
(Date:12/6/2016)... , December 6, 2016 According to a ... Microneedle), Material (Polymer, Glass, Silicon), Application (Genomics, Proteomics, Capillary Electrophoresis, POC, ... MarketsandMarkets, the global market is projected to reach USD 8.78 Billion ... of 19.2% during the forecast period (2016 to 2021). ... ...
Breaking Biology Technology:
(Date:12/5/2016)... 2016  The Office of Justice Programs, National ... Scans Enhance or Replace Medico Legal Autopsies?" on ... or replacing forensic autopsies with postmortem X-ray computed ... In response to recommendations made by The National ... scans as a potential component of medicolegal death ...
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a privately ... products for the objective detection of concussion and other ... has successfully completed a meeting with the U.S. Food ... blood test Pre-Submission Package. During the meeting company representatives ... as a precursor to commencement of a planned pilot ...
(Date:11/22/2016)... According to the new market research report "Biometric ... Signature, Voice), Multi-Factor), Component (Hardware and Software), Function (Contact and Non-contact), Application, ... is expected to grow from USD 10.74 Billion in 2015 to reach ... and 2022. Continue Reading ... ...
Breaking Biology News(10 mins):